Zenas BioPharma, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
Zenas BioPharma, Inc. (ZBIO) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements of $21.15 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-11.
Financial Statements › Notes › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements · last filed 2025-03-11
- Zenas BioPharma, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2024 was $21.15M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 12 month |
|---|---|
| 2024-12-31 | $21.15M 10-K · filed 2025-03-11 |